Literature DB >> 15746983

Influence of glucocorticoids on human osteoclast generation and activity.

Sutharshani Sivagurunathan1, Meloni M Muir, Tara C Brennan, J Paul Seale, Rebecca S Mason.   

Abstract

UNLABELLED: Using human peripheral blood mononuclear cells as osteoclast precursors, we showed that dexamethasone stimulated osteoclast generation at a pharmacological concentration but did not affect the life span of human osteoclasts. Dexamethasone also dose-dependently increased signals for osteoclastogenesis.
INTRODUCTION: Glucocorticoid-induced osteoporosis is a common and serious disease. Glucocorticoids predominantly affect osteoblast proliferation and life span. Much of the bone loss is caused by reduced bone formation, but there is also an element of increased bone resorption.
MATERIALS AND METHODS: Human peripheral blood mononuclear cells were cultured on whale dentine and induced to differentiate to osteoclasts by RANKL and human macrophage-colony stimulating factor (M-CSF). Osteoclast activity was quantified by pit area. RANKL and osteoprotegerin (OPG) expression in osteoblasts were measured by real-time RT-PCR.
RESULTS: In the early phase of osteoclast generation (0-16 days), cultures from two different donors showed that dexamethasone at 10(-8) M increased pit area by 2.5-fold, whereas lower concentrations had no effect. At the highest dexamethasone concentration (10(-7) M), pit area was reduced. In 21-day cultures from three other donors, a similar increase was seen with dexamethasone at 10(-8) M. There was, however, no evidence of increased life span of osteoclasts with dexamethasone. In human primary osteoblasts, dexamethasone dose-dependently reduced OPG and increased RANKL expression as measured by quantitative real time RT-PCR.
CONCLUSION: These data provide some explanation at a cellular and molecular level for the observed increase in bone resorption seen in patients treated with glucocorticoids and indicate that there are clear direct effects of glucocorticoids on bone resorption in human cell systems that may differ from other species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15746983     DOI: 10.1359/JBMR.041233

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

Review 1.  Review of new guidelines for the management of glucocorticoid induced osteoporosis.

Authors:  Swamy R Venuturupalli; Wendy Sacks
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 2.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

3.  Osteoblasts play key roles in the mechanisms of action of strontium ranelate.

Authors:  T C Brennan; M S Rybchyn; W Green; S Atwa; A D Conigrave; R S Mason
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 4.  Osteoprotegerin as a potential therapy for osteoporosis.

Authors:  Neveen A T Hamdy
Journal:  Curr Osteoporos Rep       Date:  2005-12       Impact factor: 5.096

5.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

6.  Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers.

Authors:  Sungtae Kim; Miwa Yamazaki; Lee A Zella; Nirupama K Shevde; J Wesley Pike
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

8.  An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

Authors:  Robert D Nerenz; Melissa L Martowicz; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2008-01-17

9.  The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions.

Authors:  Cristina Vincent; Masakazu Kogawa; David M Findlay; Gerald J Atkins
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

10.  A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.

Authors:  Monica Ibañez; Ana M Ortiz; Isabel Castrejón; J Alberto García-Vadillo; Inmaculada Carvajal; Santos Castañeda; Isidoro González-Alvaro
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.